Leanne Minall
About Leanne Minall
Leanne Minall is the Head of Science at Phare Bio, specializing in nucleic acid therapeutics and has over 12 years of experience in the field, including work on the Pfizer/BioNTech COVID vaccine.
Title and Position
Leanne Minall currently serves as the Head of Science. In this capacity, she oversees scientific research and development projects and provides strategic direction for research initiatives.
Experience in Nucleic Acid Therapeutics
Leanne Minall has over 12 years of experience working in the field of nucleic acid therapeutics. Her portfolio includes significant contributions to the Pfizer/BioNTech COVID-19 vaccine and work with adenoviral vectors. She has been involved in both early-stage research and later-stage projects including the design of RNA-lipid nanoparticle products and the development of GMP-compliant production processes.
Expertise in Drug Development
Leanne Minall possesses deep expertise in the chemistry of nucleic acid-based drug products, virus-like particles, and lipid nanoparticles. Her knowledge is crucial for the development and optimization of novel therapeutic products. She applies this expertise to help direct R&D and strategy at the non-profit, AI-lead, antibiotic developer Phare Bio, in collaboration with MIT.
Education and Postdoctoral Research
Leanne Minall completed her D.Phil. in Chemical Biology at Oxford University. Following this, she conducted postdoctoral research focused on HIV vaccine design, T-cell therapies, and hydrogel drug delivery technologies. Her academic and research background provides a robust foundation for her work in the field of nucleic acid therapeutics and drug development.